A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)

Clinical trial NCT06585787 · RECRUITING

Trial details

NCT number: NCT06585787
Sponsor: Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Status: RECRUITING
Phase: Phase 3
Study type: INTERVENTIONAL

Alzheimer Disease

Start date: 2024-09-26
Primary completion: 2026-11-24
Enrollment: 406

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.